> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Draft Guide on Enhancing Trial Diversity
- URL: https://www.fdaweb.com/draft-guide-on-enhancing-trial-diversity/
- Published: 2019-06-07T12:00:00.000Z
- Updated: 2026-09-15T01:31:28.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144285

*Federal Register* notice: FDA has made available a draft guidance entitled “Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs.” The document recommends approaches that clinical trial sponsors can take to broaden eligibility criteria, when scientifically and clinically appropriate, and increase enrollment of underrepresented populations in their clinical trials. It also reflects FDA policy encouraging inclusion in clinical trials of participants representative of the broad population of patients who will be exposed to a marketed drug and is being issued to satisfy an FDA Reauthorization Act of 2017 mandate. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-06-07/pdf/2019-11978.pdf?ref=fdaweb.com).